Lynozyfic wins FDA accelerated approval for treating RRMM adults
Linvoseltamab, now branded as Lynozyfic, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for treating adults with relapsed or refractory…
Michela Luciano, PhD, Science Writer—
Articles by Michela Luciano, PhD
Phase 1 trial of STX-0712 for rare leukemia CMML doses first patient
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
Immunotherapy implant promising for treating pancreatic cancers
A new approach in immunotherapy that can safely boost the body’s immune response has shown promise in hard-to-treat tumors like pancreatic cancers, a study…
CAN-2409 combo therapy shows survival benefits in brain cancer
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…
